R R

What Is a Keratolimbal Allograft (KLAL)?

A keratolimbal allograft (KLAL) is a surgical transplant of donor limbal tissue used to treat limbal stem cell deficiency. The limbus contains stem cells that help maintain a healthy corneal surface, and deficiency can lead to chronic pain, scarring, and poor vision. In KLAL, limbal tissue from a deceased donor is placed on the recipient eye to help restore the ocular surface. Because the tissue is allogeneic, long-term follow-up and immunosuppression planning are often part of care.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is a Keratolimbal Allograft (KLAL)?

A keratolimbal allograft (KLAL) is a surgical transplant of donor limbal tissue used to treat limbal stem cell deficiency. The limbus contains stem cells that help maintain a healthy corneal surface, and deficiency can lead to chronic pain, scarring, and poor vision. In KLAL, limbal tissue from a deceased donor is placed on the recipient eye to help restore the ocular surface. Because the tissue is allogeneic, long-term follow-up and immunosuppression planning are often part of care.

read more about keratolimbal allograft klal ...

Copy this HTML:

Copy HTML Copied!

Why Is a Keratolimbal Allograft (KLAL) Done?

KLAL is most often used when the eye lacks enough functioning limbal stem cells to keep the cornea clear and stable. It is commonly considered for severe or bilateral limbal stem cell deficiency where an autologous donor option is not appropriate. The goal is to rebuild a healthier ocular surface so the cornea can re-epithelialize properly and stay protected.

  • Severe chemical or thermal injury
  • Immune-mediated ocular surface disease such as Stevens-Johnson syndrome
  • Congenital conditions affecting the limbus such as aniridia

How Does KLAL Work?

In KLAL, donor limbal tissue attached to a corneoscleral carrier is prepared and secured around the recipient limbus. The surgeon typically removes abnormal surface tissue and places the graft to deliver limbal stem cells and supportive niche tissue. The graft helps reduce conjunctival overgrowth onto the cornea and supports more normal corneal epithelial healing.

Some patients later need a separate corneal transplant for vision once the surface is stable, because KLAL is primarily aimed at surface rehabilitation.

Recovery and Aftercare

Recovery focuses on protecting the ocular surface while the graft integrates and the epithelium stabilizes. Patients often use prescribed topical drops to control inflammation, prevent infection, and support healing. Because rejection risk is significant, clinicians may recommend systemic immunosuppression and regular monitoring based on overall risk and medical history.

Frequent follow-up visits are important to check epithelial healing, eye pressure, and early signs of rejection or infection.

Risks and Complications

KLAL carries a meaningful risk of immunologic rejection because donor tissue is transplanted to the eye. Ocular complications can include persistent epithelial defects, inflammation, infection, surface breakdown, or the need for additional surgeries. Systemic immunosuppression, when used, can also carry body-wide risks, so coordination with a medical team is important.

Prompt evaluation is recommended for increasing redness, pain, new light sensitivity, discharge, or worsening vision.

FAQs on Keratolimbal Allograft (KLAL)

Is KLAL the same as a standard corneal transplant?

No. KLAL primarily replaces limbal tissue to restore the ocular surface, while a standard corneal transplant replaces corneal tissue to improve clarity. Some patients need both procedures, often in stages, depending on surface stability and corneal scarring.

Where does the donor tissue come from?

KLAL typically uses limbal tissue from a deceased donor corneoscleral rim. This allows a larger amount of limbal tissue to be transplanted than many living-donor techniques.

Does KLAL restore vision right away?

Not always. Many patients first notice improved comfort and a more stable surface, while vision improvement depends on corneal clarity and other eye conditions. If the cornea remains scarred, a later optical corneal transplant may be considered after the surface is stable.

Will you always need immunosuppression after KLAL?

Many KLAL protocols include systemic immunosuppression to reduce rejection risk, but the exact plan depends on your overall health, cause of disease, and surgeon preference.

Your care team will weigh benefits and risks and may coordinate with another clinician to monitor labs and side effects if systemic therapy is used.

References

Keratolimbal Allograft. EyeWiki. https://eyewiki.org/Keratolimbal_Allograft. Date Accessed February 2, 2026.

Keratolimbal allograft transplantation. PubMed, National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/28379858/. Date Accessed February 2, 2026.

Homologous penetrating central limbo-keratoplasty. PubMed, National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/10634559/. Date Accessed February 2, 2026.

Long-term results of allogenic penetrating limbo-keratoplasty. PubMed, National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/27768117/. Date Accessed February 2, 2026.

Deep anterior lamellar limbo-keratoplasty for bilateral limbal stem cell deficiency and stromal scarring. PubMed, National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/35863285/. Date Accessed February 2, 2026.